Elsevier

The Lancet

Volume 367, Issue 9523, 20–26 May 2006, Pages 1631-1633
The Lancet

Comment
Clinical trial registration: transparency is the watchword

https://doi.org/10.1016/S0140-6736(06)68708-4Get rights and content

First page preview

First page preview
Click to open first page preview

References (17)

  • AM Gülmezoglu et al.

    WHO facilitates international collaboration in setting standards for clinical trial registration

    Lancet

    (2005)
  • P Cleaton-Jones

    Research injury in clinical trials in South Africa

    Lancet

    (2006)
  • H Pearson

    Tragic drug trial spotlights potent molecule

    Nature

    (2006)
  • GD Curfman et al.

    Expression of concern: Bombardier et al. “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.” N Engl J Med 2000; 243: 1520–28

    N Engl J Med

    (2005)
  • J Stephens

    Pfizer faulted over drug trials in Nigeria

    Washington Post

    (May 7, 2006)
  • NA Patsopoulos et al.

    Origin and funding of the most frequently cited papers in medicine: database analysis

    BMJ

    (2006)
  • R Sykes

    Being a modern pharmaceutical company: involves making information available on clinical trial programmes

    BMJ

    (1998)
  • K Dickersin et al.

    Registering clinical trials

    JAMA

    (2003)
There are more references available in the full text version of this article.

Cited by (138)

  • Principles and applications of metaresearch

    2022, Contemporary Research Methods in Pharmacy and Health Services
  • Meta-research in pharmacy: Time for a look in the mirror

    2021, Research in Social and Administrative Pharmacy
View all citing articles on Scopus
View full text